Savella (Milnacipran): An Off-Label treatment for MDD and GAD
How milnacipran works, what depression and anxiety studies suggest, and the benefits and trade-offs worth discussing with your prescriber.

In this article
Savella is best known in the United States as a fibromyalgia medicine, but its active ingredient, milnacipran, also has a history in depression treatment. That makes it worth understanding when you are exploring options—especially when pain and mood symptoms overlap. The evidence for depression is more developed than the early findings for anxiety, so those possibilities deserve separate conversations.1246
What is Savella—and what is it approved for?
Savella is a serotonin-norepinephrine reuptake inhibitor, or SNRI. It received U.S. approval in 2009 for fibromyalgia. Using it for major depressive disorder (MDD) or generalized anxiety disorder (GAD) in the U.S. is off-label: neither condition is an FDA-approved indication for Savella.1
The international picture is different. Milnacipran is authorized for adult major depressive episodes in France. Its U.S. status should not be mistaken for a finding that it cannot treat depression; the relevant questions are what clinical studies show and whether it fits a particular person's needs.245
How its mechanism of action works
Nerve cells use chemical messengers to communicate. Transporter proteins help clear serotonin and norepinephrine after they are released. Milnacipran inhibits those transporters, slowing reuptake rather than supplying the messengers itself. This changes signaling through systems involved in mood and pain processing.28
This dual action has been observed in people, not just laboratory models: a PET brain-imaging study found that milnacipran occupied both serotonin and norepinephrine transporters in patients with depression.3
Its balance of activity also differs from some other SNRIs. Laboratory uptake experiments found relatively strong norepinephrine-transporter inhibition alongside serotonin effects. That is a pharmacological distinction, not a ranking of which antidepressant will work best for you.8
What do depression studies show?
Milnacipran's antidepressant potential is supported by controlled clinical research. In a five-week randomized trial involving 58 hospitalized patients with major depression, it improved depression measures more than placebo. This was a small, older study, but it provides direct evidence beyond a theory about how the drug works.4
A later exploratory trial randomized 195 adults with moderate-to-severe depression to milnacipran or venlafaxine for 24 weeks. Both groups improved. At eight weeks, roughly 42% in each treatment group met the study's remission threshold in its efficacy analysis—meaning symptoms had fallen below a defined level.5
That comparison had no placebo group and was not designed to establish that the medicines are interchangeable. It nevertheless adds encouraging clinical evidence for milnacipran as an antidepressant option, rather than merely a pain treatment with a speculative mood benefit.5
Could it also help generalized anxiety?
There is an encouraging early signal. An eight-week open study enrolled 12 people with GAD. Two stopped because of adverse effects; the 10 who completed treatment had substantial reductions in anxiety scores. These results describe the completers, not everyone who started.6
Because the study had no placebo group and participants knew they were receiving treatment, it cannot establish how much improvement came from milnacipran itself. The findings support further investigation and a thoughtful clinical discussion—not treating the anxiety evidence as equivalent to the depression research.6
Potential benefits and practical trade-offs
A useful reason to discuss milnacipran is that it offers another SNRI option with depression research behind it. If fibromyalgia is also part of the picture, its established role in that condition makes it particularly relevant to ask how pain and mood treatment could fit together. That is an individualized treatment question, not evidence that one medicine will necessarily address both.145
Side-effect priorities matter too. Fibromyalgia trials reported a small average weight decrease, but that is not a promise of weight loss or proof of superiority over other antidepressants. Sexual side effects can occur, and withdrawal symptoms remain possible. It is more useful to discuss your particular concerns than to label Savella universally easier to tolerate.17
Side effects and safety checks that matter
Common effects include nausea, constipation, headache, dizziness, sweating, and sleep difficulty. Tell your prescriber if these are persistent or interfere with daily life rather than assuming you have to put up with them.2
Fever with confusion, marked agitation, or muscle rigidity—especially after combining medicines—needs urgent assessment for serotonin syndrome. If you feel unable to stay safe, seek emergency help.2
- Blood pressure and pulse: check these before treatment and periodically afterward, because milnacipran can raise both.2
- Interactions: MAO inhibitors must not be combined with Savella; a prescriber must manage the required switching intervals. Other serotonin-affecting medicines and supplements need review too.2
- Health history: discuss bipolar symptoms, seizures, kidney or liver disease, substantial alcohol use, bleeding risks, pregnancy, and breastfeeding.7
- Mood changes: report new suicidal thoughts, sharply worsening mood, or unusual agitation promptly. The antidepressant boxed warning includes increased suicidal-thinking and behavior risk in children, adolescents, and young adults; Savella is not approved for children.7
Taking it, allowing time, and stopping safely
Milnacipran is generally taken twice daily after a low starting dose is gradually increased. Food may reduce stomach upset. Follow your own prescription rather than borrowing a dosing schedule from a study.7
Antidepressant effects develop over time; French product information describes improvement emerging after a delay of around one to three weeks, with continued treatment and follow-up needed. Agree on when your prescriber will review progress.2
Do not stop suddenly. Withdrawal can include dizziness, anxiety, sleep disturbance, and unusual sensations; arrange a gradual, individualized reduction with your prescriber.7
A hopeful option, with a clear plan
The takeaway is not that Savella is a hidden cure or that its U.S. indication rules out mental-health benefits. Milnacipran has genuine depression research behind it, while anxiety findings remain preliminary. Both facts can be held together without dismissing its potential.456
Ask: What symptoms are we targeting? Why consider this rather than another option? How will we track mood, anxiety, pain, and tolerability? What would make us change the plan? Medication can be one part of care alongside therapy and practical support. Having more options is valuable; matching an option to your life is what makes it useful.
By Birk Gundersen, RN, BSN.
References
- Savella — current U.S. prescribing information on DailyMed: approval, indications, monitoring, interactions, and weight findings
- French public medicines database — milnacipran: authorized depression use and product information
- Human PET study (2013) — serotonin and norepinephrine transporter occupancy with milnacipran in depression
- Macher et al. (1989) — randomized, placebo-controlled milnacipran trial in hospitalized patients with major depression
- Olié et al. (2010) — 24-week randomized exploratory comparison of milnacipran and venlafaxine in major depression
- Tsukamoto et al. (2004) — eight-week open study of milnacipran in generalized anxiety disorder
- MedlinePlus — milnacipran: taking the medicine, precautions, adverse effects, and withdrawal
- Laboratory transporter study (2004) — comparison of milnacipran's monoamine uptake and binding activity
